{"transactions":[{"id":3986459,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":157677,"kind":"organization","name":"Takeda Pharmaceuticals International AG","position":1,"cik":"0001688140","reported_name":"Takeda Pharmaceuticals International AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2662,"kind":"organization","name":"TAKEDA PHARMACEUTICAL CO LTD","symbol":"TAK","position":2,"cik":"0001395064","reported_name":"TAKEDA PHARMACEUTICAL CO LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":168139,"kind":"person","name":"Takeda A/S","position":3,"cik":"0001716380","reported_name":"Takeda A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":168140,"kind":"organization","name":"Takeda Europe Holdings B.V.","position":4,"cik":"0001716379","reported_name":"Takeda Europe Holdings B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":168141,"kind":"person","name":"Takeda Pharma A/S","position":5,"cik":"0001716226","reported_name":"Takeda Pharma A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-03-21T21:42:49.000Z","date":"2018-03-19","kind":"purchase","acquired":true,"shares":7420625,"price":18.67,"value":138543068.75,"ownership":{"direct":false,"nature":"By Millennium\nPharmaceuticals\n, Inc."},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"On March 19, 2018, Takeda Pharmaceuticals International AG (\"TPIZ\") sold 7,420,625 shares of common stock of Myovant Sciences Ltd. to Millennium Pharmaceuticals, Inc. (\"Millennium\"). As of the date of this filing: Millennium is owned by Takeda Pharmaceuticals U.S.A., Inc. (\"TPUSA\"); 41.05% of the outstanding common stock of TPUSA is owned by TPIZ and 58.95% of the outstanding common stock of TPUSA is owned by Takeda Pharmaceuticals Company Limited (''TPC\"); 86.831% of the outstanding shares of TPIZ are owned by Takeda Pharma A/S (Denmark) (\"TPAS\") and 13.1680% of the outstanding shares of TPIZ are owned by Takeda Europe Holdings BY (Netherlands) (''TEHBV\"); TPAS is owned by Takeda A/S (Denmark) (''T AS\"); 76.09% of the outstanding shares of TAS are owned by TPC and 23.91% of the outstanding shares of TAS are owned by TEHBV. TEHBV is wholly-owned by TPC."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F2","text":"(Continued from Footnote 1) Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On March 19, 2018, Takeda Pharmaceuticals International AG (\"TPIZ\") sold 7,420,625 shares of common stock of Myovant Sciences Ltd. to Millennium Pharmaceuticals, Inc. (\"Millennium\"). As of the date of this filing: Millennium is owned by Takeda Pharmaceuticals U.S.A., Inc. (\"TPUSA\"); 41.05% of the outstanding common stock of TPUSA is owned by TPIZ and 58.95% of the outstanding common stock of TPUSA is owned by Takeda Pharmaceuticals Company Limited (''TPC\"); 86.831% of the outstanding shares of TPIZ are owned by Takeda Pharma A/S (Denmark) (\"TPAS\") and 13.1680% of the outstanding shares of TPIZ are owned by Takeda Europe Holdings BY (Netherlands) (''TEHBV\"); TPAS is owned by Takeda A/S (Denmark) (''T AS\"); 76.09% of the outstanding shares of TAS are owned by TPC and 23.91% of the outstanding shares of TAS are owned by TEHBV. TEHBV is wholly-owned by TPC."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"(Continued from Footnote 1) Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"On March 19, 2018, Takeda Pharmaceuticals International AG (\"TPIZ\") sold 7,420,625 shares of common stock of Myovant Sciences Ltd. to Millennium Pharmaceuticals, Inc. (\"Millennium\"). As of the date of this filing: Millennium is owned by Takeda Pharmaceuticals U.S.A., Inc. (\"TPUSA\"); 41.05% of the outstanding common stock of TPUSA is owned by TPIZ and 58.95% of the outstanding common stock of TPUSA is owned by Takeda Pharmaceuticals Company Limited (''TPC\"); 86.831% of the outstanding shares of TPIZ are owned by Takeda Pharma A/S (Denmark) (\"TPAS\") and 13.1680% of the outstanding shares of TPIZ are owned by Takeda Europe Holdings BY (Netherlands) (''TEHBV\"); TPAS is owned by Takeda A/S (Denmark) (''T AS\"); 76.09% of the outstanding shares of TAS are owned by TPC and 23.91% of the outstanding shares of TAS are owned by TEHBV. TEHBV is wholly-owned by TPC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"(Continued from Footnote 1) Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein."}],"balance_after":7420625,"source":{"system":"sec-edgar","filing":"0000899243-18-008309","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1716380/000089924318008309/doc4.xml","form_type":"4"}},{"id":3986458,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":157677,"kind":"organization","name":"Takeda Pharmaceuticals International AG","position":1,"cik":"0001688140","reported_name":"Takeda Pharmaceuticals International AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2662,"kind":"organization","name":"TAKEDA PHARMACEUTICAL CO LTD","symbol":"TAK","position":2,"cik":"0001395064","reported_name":"TAKEDA PHARMACEUTICAL CO LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":168139,"kind":"person","name":"Takeda A/S","position":3,"cik":"0001716380","reported_name":"Takeda A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":168140,"kind":"organization","name":"Takeda Europe Holdings B.V.","position":4,"cik":"0001716379","reported_name":"Takeda Europe Holdings B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":168141,"kind":"person","name":"Takeda Pharma A/S","position":5,"cik":"0001716226","reported_name":"Takeda Pharma A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-03-21T21:42:49.000Z","date":"2018-03-19","kind":"sale","acquired":false,"shares":7420625,"price":18.67,"value":138543068.75,"ownership":{"direct":true},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"On March 19, 2018, Takeda Pharmaceuticals International AG (\"TPIZ\") sold 7,420,625 shares of common stock of Myovant Sciences Ltd. to Millennium Pharmaceuticals, Inc. (\"Millennium\"). As of the date of this filing: Millennium is owned by Takeda Pharmaceuticals U.S.A., Inc. (\"TPUSA\"); 41.05% of the outstanding common stock of TPUSA is owned by TPIZ and 58.95% of the outstanding common stock of TPUSA is owned by Takeda Pharmaceuticals Company Limited (''TPC\"); 86.831% of the outstanding shares of TPIZ are owned by Takeda Pharma A/S (Denmark) (\"TPAS\") and 13.1680% of the outstanding shares of TPIZ are owned by Takeda Europe Holdings BY (Netherlands) (''TEHBV\"); TPAS is owned by Takeda A/S (Denmark) (''T AS\"); 76.09% of the outstanding shares of TAS are owned by TPC and 23.91% of the outstanding shares of TAS are owned by TEHBV. TEHBV is wholly-owned by TPC."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F2","text":"(Continued from Footnote 1) Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On March 19, 2018, Takeda Pharmaceuticals International AG (\"TPIZ\") sold 7,420,625 shares of common stock of Myovant Sciences Ltd. to Millennium Pharmaceuticals, Inc. (\"Millennium\"). As of the date of this filing: Millennium is owned by Takeda Pharmaceuticals U.S.A., Inc. (\"TPUSA\"); 41.05% of the outstanding common stock of TPUSA is owned by TPIZ and 58.95% of the outstanding common stock of TPUSA is owned by Takeda Pharmaceuticals Company Limited (''TPC\"); 86.831% of the outstanding shares of TPIZ are owned by Takeda Pharma A/S (Denmark) (\"TPAS\") and 13.1680% of the outstanding shares of TPIZ are owned by Takeda Europe Holdings BY (Netherlands) (''TEHBV\"); TPAS is owned by Takeda A/S (Denmark) (''T AS\"); 76.09% of the outstanding shares of TAS are owned by TPC and 23.91% of the outstanding shares of TAS are owned by TEHBV. TEHBV is wholly-owned by TPC."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"(Continued from Footnote 1) Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-18-008309","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716380/000089924318008309/doc4.xml","form_type":"4"}}]}